Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE-IT phase 3 study of PB2452 for reversal of ticagrelor in emergency bleeding or urgent surgery
2019-004457-92Phase 3Completed
- Sponsor
- SFJ Pharmaceuticals
- Start
- Oct 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bentracimab in Not applicable, sponsored by SFJ Pharmaceuticals. Primary endpoint: Primary reversal endpoint. Started Oct 2020; status: completed.
02
Drugs
bentracimab
03
Conditions
Not applicable
Beyond the preview
Go deeper on 2019-004457-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004457-92.